Clinical Trials Browser

Phase 2 × Antiemetics × 90 days × Clear all

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

Ependymoma, Medulloblastoma

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2 Terminated

2 enrolled 7 charts

Recurrence